LIGAND PHARMACEUTICALS INCORPORATED
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $793.2M | $15.0M |
| Jun 2022 | — | $802.4M | $5.3M |
| Sep 2022 | — | $816.3M | $4.1M |
| Dec 2022 | — | $597.5M | $45.0M |
| Mar 2023 | — | $646.3M | $88.7M |
| Jun 2023 | — | $664.9M | $28.4M |
| Sep 2023 | — | $667.9M | $19.3M |
| Dec 2023 | — | $700.9M | $23.0M |
| Mar 2024 | — | $806.5M | $50.1M |
| Jun 2024 | — | $775.2M | $18.1M |
| Sep 2024 | — | $841.2M | $63.6M |
| Dec 2024 | — | $830.4M | $72.3M |
| Mar 2025 | — | $795.6M | $48.0M |
| Jun 2025 | — | $827.3M | $67.7M |
| Sep 2025 | — | $950.2M | $139.4M |
| Dec 2025 | — | $1.02B | $174.9M |
| Mar 2026 | — | $997.3M | $115.1M |
| Jun 2026 | $1.13B | $967.5M | $1.01B |